2025-11-17T18:11:37-06:00 2024-12-31 454205322 HW LLP 16133 VENTURA BLVD STE 700 ENCINO CA 914362406 990 2024-01-01 851457272 EPIGENETIC CLOCK DEVELOPMENT FOUNDATION EPIG 8189213980 1124 W CARSON ST MRL BLDG 3RD FLO TORRANCE CA 90502 ROBERT BROOKE EXECUTIVE DIRECTOR 8189213980 2025-11-17 1 1 LOUIS HAMEL P00392169 8189213980 2025-11-17 2024 2025-03-06 01:10:19Z ROBERT BROOKE 1124 W CARSON ST MRL BLDG 3RD FLOOR TORRANCE CA 90502 2073205 0 X WWW.CLOCKFOUNDATION.ORG X 2020 CA THE EPIGENETIC CLOCK DEVELOPMENT FOUNDATION ("CLOCK FOUNDATION") WAS FORMED TO ENABLE RIGOROUS MEDICAL RESEARCH ON AGING AND LONGEVITY. OUR RESEARCH MAINLY INVOLVES USE AND DEVELOPMENT OF NEW AGING BIOMARKERS KNOWN AS EPIGENETIC CLOCKS FOR TESTING THE EFFECTIVENESS OF LONGEVITY TREATMENTS WITHIN PRECLINICAL AND CLINICAL STUDIES. 3 3 6 0 0 0 6600 4800 1921950 1570700 289 17 956553 497688 2885392 2073205 0 0 0 0 284545 282712 0 0 0 3168916 1545699 3453461 1828411 -568069 244794 954701 330376 945905 186603 8796 143773 X THE CLOCK FOUNDATION WAS FORMED FOR THE SPECIFIC AND PRIMARY PURPOSE OF CONDUCTING MEDICAL RESEARCH ON AGING AND AGE-RELATED DISEASES. DEVELOPING THE EPIGENETIC AGING CLOCK INTO A USEFUL TECHNOLOGY WILL REQUIRE MEDICAL RESEARCH ON AGING AND AGE-RELATED DISEASES. CONSEQUENTLY, THE ACTIVITY WILL ADVANCE CLOCK FOUNDATION'S SPECIFIC PURPOSE OF CONDUCTING MEDICAL RESEARCH ON AGING AND AGE-RELATED DISEASES. IF THE MEDICAL RESEARCH OF THE CLOCK FOUNDATION IS SUCCESSFUL AND THE FDA APPROVES THE CLOCK FOUNDATION'S TESTING METHOD, MANY NEW DRUGS OR TREATMENTS THAT ARE ABLE TO REVERSE EPIGENETIC AGING COULD THEN BE FORMALLY APPROVED BY THE FDA FOR THE TREATMENT OF AGING AND FOR USE IN PREVENTATIVE MEDICINE. 0 0 81341 INTERNAL RESEARCH PROGRAM:SINCE INCEPTION WE HAVE FOCUSED ON DEVELOPMENT OF EPIGENETIC CLOCKS AS A KEY ENABLING TECHNOLOGY FOR THE FIELD. WE ARE A SMALL TEAM OF DEDICATED RESEARCHERS, AND THIS YEAR WE WORKED ESPECIALLY ON DEVELOPMENT OF NOVEL EPIGENETIC TESTING APPROACHES, AND ON BUILDING OF ADDITIONAL TESTING INFRASTRUCTURE TO SUPPORT GLOBAL STUDIES. THE HORVATH MAMMALIAN ARRAY, A KEY ENABLING TECHNOLOGY FOR TRANSLATIONAL AGING RESEARCH, HAS BEEN NOW DESCRIBED AND USED IN MULTIPLE SCIENTIFIC PAPERS INCLUDING ONES PUBLISHED IN SCIENCE, NATURE COMMUNICATIONS, AND NATURE AGING. ADDITIONAL PAPERS HAVE BEEN RELEASED ON DOGS IN PNAS, CATS, HORSES, SHEEP, MARSUPIALS, NAKED MOLE RATS, AND MANY OTHERS. THE PAPERS DESCRIBE THE DISCOVERY OF UNIVERSAL MAMMALIAN AGING CLOCKS & EPIGENETIC PREDICTORS OF MAXIMUM LIFESPAN, AND MORE RECENT PAPERS DESCRIBE USE FOR MONITORING OF TREATMENT EFFECTIVENESS IN PRECLINICAL STUDIES. 988760 2068388 EXTERNAL RESEARCH COLLABORATIONS: INTERVENTIONAL LONGEVITY STUDIES WE CONTINUE TO CONDUCT MANY NEW INTERVENTIONAL STUDIES EACH YEAR, FOR CLINICAL TRIALS AND ALSO PRECLINICAL STUDIES. THIS INCLUDES STUDIES ON PLASMAPHARESIS, YOUNG PLASMA TREATMENT, STEM CELL EXOSOMES, BONE MARROW TRANSPLANTS, UMBILICAL CORD PLASMA, ANTIRETROVIRAL TREATMENTS, AND A SENOLYTIC GENE THERAPY. WILDLIFE CONSERVATION MANY RESEARCHERS NOW ALSO COMMONLY USE EPIGENETIC AGING CLOCKS TO PREDICT THE AGE ANIMALS IN THE WILD, INCLUDING WHALES, DOLPHINS, ELK, POLAR BEARS, AND MANY OTHER SPECIES. THE TESTING IS BEING DEVELOPED AS AN ALTERNATIVE TO MUCH MORE INVASIVE MEASURES SUCH AS TOOTH EXTRACTION, ENABLING ROUTINE STUDIES ON THE EFFECTS OF POPULATION STRESSORS SUCH AS HABITAT LOSS ON BIOLOGICAL AGING. MECHANISMS OF AGING STUDIES THERE WERE MANY NOTABLE MECHANISTIC STUDIES THIS PAST YEAR ON THE ROLE OF CELLULAR HETEROGENEITY IN EPIGENETIC CLOCK RESULTS, THE SHORT-TERM EFFECTS OF EXERCISE IN PROFESSIONAL SOCCER PLAYERS, TESTING MANY DIFFERENT TYPES OF CELLULAR REPROGRAMMING, THE EFFECTS OF HETEROCHRONIC PARABIOSIS AND BONE MARROW TRANSPLANTS. 744841 4817 OTHER PROGRAM SERVICES 744841 4817 1814942 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 4 0 6 0 0 0 0 0 0 0 0 0 0 0 X 3 3 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 1 1 1 1 0 CA X X ROBERT BROOKE 5138699793 1124 W CARSON ST BLDG 3RD TORRANCE CA 90502 ROBERT BROOKE EXECUTIVE DIRECTOR 40.00 X X 120000 0 0 STEFAN HORVATH DIRECTOR, CHAIRMAN 0.00 X 0 0 0 DEAN PRISSMAN DIRECTOR 0.00 X 0 0 0 120000 0 0 1 0 0 0 VUGENE LLC 625 KENMOOR AVE SUITE 301 PMB 965 GRAND RAPIDS MI 49546 BIOINFORMATICS CONSULTING 111885 1 4800 4800 FEE FOR SERVICE INCOME 541700 1570700 1570700 1570700 17 17 SALES 541700 497688 497688 497688 2073205 2068405 0 0 240000 240000 18824 18824 23888 23888 4683 4683 8786 8786 39906 39906 25002 25002 70947 70947 1957 1957 56208 56208 SPONSORED EPIGENETIC TE 988760 988760 RESEARCH & DEVELOPMENT 179785 179785 TREATMENT TESTING SERVI 81341 81341 COMPUTER AND TECH EXP 38505 38505 49819 49819 1828411 1814942 13469 0 157312 86588 766383 214111 245 245 30761 29432 954701 330376 945905 186603 945905 186603 X 8796 143773 8796 143773 954701 330376 244794 -109817 0 X 0 0 0 X HARBOR UCLA MEDICAL CENTER TORRANCE CA 0 SECURITY DEPOSITS 3600 INTELLECTUAL PROPERTY 25232 UNDEPOSITED FUND 600 29432 FORM 990, PART VI, SECTION B, LINE 11B FINANCIALS ARE PREPARED BY A BOOKKEEPER WITH INPUT FROM A CERTIFIED PUBLIC ACCOUNTANT. TAX ACCOUNTANTS PREPARE THE FILING. EXECUTIVE DIRECTOR REVIEWS AND RECEIVES INPUT FROM LEGAL COUNSEL PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C OFFICERS, DIRECTORS, EMPLOYEES AND VOLUNTEERS OF EPIGENETIC CLOCK DEVELOPMENT FOUNDATION ARE ENCOURAGED TO BRING ANY ALLEGED UNLAWFUL ACTIVITY, POLICY OR PRACTICE TO THE ATTENTION OF EPIGENETIC CLOCK DEVELOPMENT FOUNDATION. A PROTEST, CONCERN OR COMPLAINT SHALL BE MADE IN WRITING TO THE PRESIDENT OF EPIGENETIC CLOCK DEVELOPMENT FOUNDATION. FORM 990, PART VI, SECTION B, LINE 15 BOARD MEMBERS AND DONOR ORGANIZATIONS ARE MADE AWARE OF AND ABLE TO REVIEW EXECUTIVE AND KEY EMPLOYEE COMPENSATION THROUGH INDEPENDENT REPORTS AND THROUGH APPROVAL OF ANNUAL BUDGETS. BOARD MEMBERS AND DONOR ORGANIZATIONS ARE MADE AWARE OF AND ARE ABLE TO REVIEW EXECUTIVE AND KEY EMPLOYEE COMPENSATION THROUGH INDEPENDENT REPORTS AND THROUGH APPROVAL OF ANNUAL BUDGETS. FORM 990, PART VI, SECTION C, LINE 19 THE DOCUMENTS ARE MADE AVAILABLE UPON REQUEST.